how long until retatrutide is fda approved When will be available for weight loss? Tirzepatide vs. Retatrutide: Key Differences

It is important to note that while GLP-1RAs have demonstrated CV safety, not all result in an actual reduction in CV adverse events, such as exenatide QW and lixisenatide, both of which were reported to be non-inferior to placebo for MACE [22, 23]

This cellular response may eventually lead to the death of DA cells, leading to disease progression.180 A study that used 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) to mimic PD-like neural injury found that neuroinflammation is aggravated in the midbrain of type 2 diabetes mice, who are more susceptible to the neurotoxicity induced by MPTP.181 This may indicate that diabetes exacerbates DA neuronal degeneration during the progression of PD, which may be mediated by neuroinflammation

LCFA, long chain fatty acid

cAMP elevation induced by GLP-1 can lead to its downstream protein kinase A (PKA) activation and enhanced signaling via cAMP-activated guanine nucleotide exchange factor (Epac) (Holz, 2004

As muscles adapt to reduced glycogen stores, localized spasms may occur, particularly in larger muscle groups

As insurers struggle with GLP-1 drug costs, some seek to wean patients off This is a KFF Health News story